GSK ends ChemoCentryx collaboration
This article was originally published in Scrip
Executive Summary
ChemoCentryx said on 3 December that GlaxoSmithKline decided not to license CCX168 and returned the rights to CCX354, thereby ending the companies' seven-year-old drug development partnership.